Close Menu

stock rating

Macquarie cited competition and potential budget cuts in downgrading Qiagen's shares, lowering its revenue and EPS estimates, and pushing down its target share price.

Analysts revised EPS and revenue estimates as well as target prices following earnings releases on Tuesday by Illumina, Life Technologies, Waters, and Becton Dickinson.

Oppenheimer increased its price target and revenue estimates on Complete Genomics, while Jefferies raised its EPS and price target for Danaher.

An analyst for the investment firm gave PacBio a "Market Perform" rating and Complete Genomics an "Outperform" rating.

Jefferies analyst Jon Wood also raised his price target on the firm's stock to $15.50 from $13, following a presentation by Complete Genomics CEO Clifford Reid at a biotech conference.

The investment firm lowered its estimates from levels predicted last week to reflect lost consumables sales on its older next-gen sequencing platforms and softer microarray consumables sales sequentially.

Analyst Dan Leonard said growth will be driven by what he expects to be record-breaking sales of Illumina's next-generation sequencing platforms, including its HiSeq, in the first and second quarters of 2011.

Macquarie Capital analyst Dane Leone gave Genomic Health an "Outperform" rating and a $34 price target, and Myriad a "Neutral" rating with a $20 share price.

Brian Weinstein expressed concern about competition in the HPV space and a stock that has tracked the overall market since 2007, but gave a thumbs up to the $355 acquisition of Cellestis.

An analyst at the investment firm said that the expanded production of Illumina's HiSeq sequencing platform is expected to result in sequential revenue growth in the first and second quarters of 2011, but revenue growth will likely abate in the third quarter.

Pages

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.